Viking Therapeutics is trading at $31.96 (-6.04%) amid broader biotech weakness and a lack of new company-specific catalysts following a sharp morning selloff.
- The downward move appears to track a general shift toward risk-off sentiment across the biotech sector.
- Investors are also continuing to digest the company's July 29 earnings results and recent clinical-trial progress.